![]() |
市場調查報告書
商品編碼
1300005
基因組學服務市場 - 按服務(下一代測序、桑格測序、微陣列)、按應用(研究、診斷)、按終端用戶(研究機構、診斷中心、契約研究組織(CRO)),預測-2032年Genomics Services Market - By Service (Next Generation Sequencing, Sanger Sequencing, Microarray), By Application (Research, Diagnostics), By End-user (Research Institutes, Diagnostic Centers, Contract Research Organization (CROs)), Forecast-2032 |
全球基因組學服務市場規模將在2032年之前呈指數級擴張。對藥物基因組學的投資不斷上升,增加了對基因組學服務的需求。通過將藥物基因組學資訊涵蓋藥物開發和處方實踐,基因組學服務有助於提高藥物的療效和安全性。識別影響藥物反應的遺傳標記,可以更好地為個別病人選擇適當的藥物、劑量和治療方案。這種最佳化可以提高治療效果,最大限度地減少藥物的不良反應,並減少試驗和錯誤的處方,從而導致基因組學服務的高採用率。
整個基因組學服務市場根據服務、應用、終端用戶和地區進行分類。
基於服務,桑格測序部分的行業價值將在2032年之前觀察到顯著收益。桑格測序的高精確度有利於其採用。此外,對於規模較小的項目、低樣本量或特定區域的定向測序,與高通量NGS平台相比,桑格測序可能是一個更實惠的選擇。這種測序對於特定區域的定向測序或確認由其他方法確定的變體特別有用。
基於應用,從2023年到2032年,診斷領域的行業佔有率將以有利可圖的複合年成長率成長。對精準醫療的認知不斷提高,增加了診斷學中對基因組學服務的需求。通過分析病人的基因構成,包括生殖系和體細胞突變,基因組學服務可以幫助確定個性化的治療方案。這包括確定目標療法,預測藥物反應,以及根據病人的基因組特徵最佳化治療方案。精準醫療的目的是通過根據個人的特定基因特徵客製化治療方案來改善治療效果。
基於終端用戶,製藥和生物技術公司部分的行業規模將在2032年之前顯著擴大。製藥和生物技術公司對藥物開發的投資不斷成長,增加了對基因組學服務的需求。這些服務有助於識別和驗證藥物開發的潛在治療目標。通過分析來自患者、疾病模型或大規模基因組數據庫的基因組數據,研究人員可以確定與疾病相關的遺傳變異、突變或基因表達模式。
從區域來看,亞太地區的基因組學服務市場價值將在2023-2032年呈現出可觀的成長。蓬勃發展的醫療保健行業,加上老年人口激增導致的慢性病的日益流行,增加了該地區對基因組學服務的投資。根據世界衛生組織,在中國,到2040年,60歲以上的人口將佔人口的28%。此外,人們對基因組學的認知不斷提高,也進一步促進了區域成長。
Global Genomics Services Market size will expand exponentially through 2032. Rising investments in pharmacogenomics have increased the demand for genomics services. By integrating pharmacogenomic information into drug development and prescribing practices, genomics services help improve drug efficacy and safety. Identifying genetic markers that influence drug response enables better selection of appropriate medications, dosages, and treatment regimens for individual patients. This optimization can enhance therapeutic outcomes, minimize adverse drug reactions, and reduce trial-and-error prescribing, leading to high adoption rate of genomics services.
The overall genomics services market is categorized based on service, application, end-user, and region.
Based on the service, industry value from the Sanger sequencing segment will observe significant gains through 2032. The high accuracy of Sanger sequencing favors its adoption. Additionally, for smaller-scale projects, low sample volumes, or targeted sequencing of specific regions, Sanger sequencing can be a more affordable option compared to high-throughput NGS platforms. This sequencing is particularly useful for targeted sequencing of specific regions or confirming variants identified by other methods.
Based on application, industry share from the diagnostics segment will grow at a lucrative CAGR from 2023 to 2032. Growing awareness about precision medicine has increased the demand for genomics services in diagnostics. By analyzing a patient's genetic makeup, including germline and somatic mutations, genomic services can help identify personalized treatment options. This includes identifying targeted therapies, predicting drug responses, and optimizing treatment regimens based on the patient's genomic profile. Precision medicine aims to improve treatment outcomes by tailoring therapies to an individual's specific genetic characteristics.
Based on end-user, industry size from the pharmaceutical & biotechnological companies segment will expand significantly through 2032. Growing investment in drug development by pharmaceutical and biotechnological companies has increased the demand for genomics services. These services help identify and validate potential therapeutic targets for drug discovery. By analyzing genomic data from patients, disease models, or large-scale genomic databases, researchers can identify genetic variants, mutations, or gene expression patterns associated with diseases.
Regionally, the Asia Pacific genomics services market value will show an appreciable growth over 2023-2032. Flourishing healthcare industry, coupled with the growing prevalence of chronic diseases attributed to the surging elderly population, has increased investments in genomics services in the region. As per WHO, in China, the population of people above 60 years will account for 28% of the population by 2040. Moreover, growing awareness about genomics is further contributing to regional growth.